vimarsana.com

Latest Breaking News On - Reata pharmaceuticals company profile - Page 4 : vimarsana.com

Citigroup Downgrades Reata Pharmaceuticals (NASDAQ:RETA) to Neutral

Citigroup cut shares of Reata Pharmaceuticals (NASDAQ:RETA – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat reports. Citigroup currently has $172.50 target price on the stock, up from their prior target price of $127.00. Other equities analysts have also recently issued reports about the […]

Reata Pharmaceuticals (NASDAQ:RETA) PT Raised to $173 00 at Robert W Baird

Reata Pharmaceuticals (NASDAQ:RETA – Free Report) had its target price lifted by Robert W. Baird from $85.00 to $173.00 in a research note published on Monday morning, Marketbeat Ratings reports. Robert W. Baird currently has an outperform rating on the stock. RETA has been the topic of several other reports. StockNews.com initiated coverage on Reata […]

Reata Pharmaceuticals (NASDAQ:RETA) Lowered to Market Perform at SVB Securities

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by equities research analysts at SVB Securities from an “outperform” rating to a “market perform” rating in a research report issued on Friday, FlyOnTheWall reports. Several other analysts have also commented on the stock. Stifel Nicolaus lowered shares of Reata Pharmaceuticals from a “buy” rating to […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.